Mandate

Vinge advises Lassie AB in its SEK 115 million financing round

May 24, 2022

Vinge has advised the pet insurance company Lassie AB in connection with a SEK 115 million financing round for the purpose of expanding the business internationally and developing the company’s app.

Lassie AB, whose business model incentivises the users to reduce their insurance costs by gaining points through preventive veterinary care, was founded by Hedda Båverud Olsson, Johan Jönsson and Sophie Wilkinson and the company has grown rapidly since its first financing round less than a year ago.

The financing round was led by the British venture capital firm, Felix Capital, and involved several current investors, among others, the institutional investors Inventure and Passion Capital as well as H&M’s chairman of the board, Karl-Johan Person, and Voi’s founder and head of marketing, Fredrik and Caroline Hjelm.

Vinge’s team consisted of Filip Öhrner, Maria Dahlin Kolvik and Viktor Lennartsson.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026